New insomnia drug HS-10506 put to the test in large safety trial
NCT ID NCT07677384
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase 3 study evaluates the safety of HS-10506, an experimental insomnia medication, in 600 Chinese adults aged 18 to 64 with insomnia disorder. Researchers track side effects, serious adverse events, and specific safety concerns over both short and long-term use. The goal is to determine whether HS-10506 is safe enough for broader use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HS-10506
What this could lead to
If safe and effective, HS-10506 could offer a new treatment option for insomnia, potentially improving sleep without serious side effects.
What could go wrong
This trial focuses on safety, not effectiveness, and results may not apply to non-Chinese populations. Side effects are possible, and the drug may not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INSOMNIA DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••